2011
Discrepancy in the assessment of jailed side branch lesions by visual estimation and quantitative coronary angiographic analysis
Shin D, Koo B, Waseda K, Park KW, Kim H, Corral M, Lansky A, Honda Y, Fearon WF, Fitzgerald PJ. Discrepancy in the assessment of jailed side branch lesions by visual estimation and quantitative coronary angiographic analysis. Catheterization And Cardiovascular Interventions 2011, 78: 720-726. PMID: 22025472, DOI: 10.1002/ccd.23049.Peer-Reviewed Original ResearchConceptsMean minimum lumen diameterQuantitative coronary angiographyFractional flow reserveSide branch lesionsDiameter stenosisSB lesionsIntraclass correlation coefficientBranch lesionsQuantitative coronary angiographic analysisCoronary angiographic analysisMinimum lumen diameterVisual estimationCoronary angiographyPressure trialAngiographic analysisAngiographic assessmentFlow reserveCore laboratoryStenosisReference diameterLesionsLumen diameterLesion lengthFunctional significance
2008
Quantitative angiographic methods for bifurcation lesions : A consensus statement from the European Bifurcation Group
Lansky A, Tuinenburg J, Costa M, Maeng M, Koning G, Popma J, Cristea E, Gavit L, Costa R, Rares A, Van Es G, Lefevre T, Reiber H, Louvard Y, Morice M. Quantitative angiographic methods for bifurcation lesions : A consensus statement from the European Bifurcation Group. Catheterization And Cardiovascular Interventions 2008, 73: 258-266. PMID: 19085918, DOI: 10.1002/ccd.21814.Peer-Reviewed Original ResearchA Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients
2002
Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry
Suntharalingam M, Laskey W, Lansky AJ, Waksman R, White L, Teirstien P, Massullo V, Rutherford B, Elman A, Kuntz RE, Popma JJ, Bonan R, Investigators T. Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry. International Journal Of Radiation Oncology • Biology • Physics 2002, 52: 1075-1082. PMID: 11958904, DOI: 10.1016/s0360-3016(01)02712-2.Peer-Reviewed Original ResearchConceptsMinimum luminal diameterPlacebo groupStent restenosisAngiographic analysisInjury lengthBinary restenosisRevascularization ratesPlacebo armSTART trialSource trainTarget vessel revascularization rateMajor adverse cardiac eventsTarget lesion revascularization rateAdverse cardiac eventsLesion revascularization rateRepeat balloon angioplastyVessel revascularization rateTarget vessel revascularizationNative coronary arteriesManagement of patientsRate of restenosisQuantitative angiographic analysisResults of patientsLate aneurysm formationPercent diameter stenosis
1999
Quantitative angiographic analysis of stent restenosis in the scripps coronary radiation to inhibit intimal proliferation post stenting (SCRIPPS) trial
Lansky A, Popma J, Massullo V, Jani S, Russo R, Schatz R, Steuterman S, Guarneri E, Wu H, Mehran R, Mintz G, Leon M, Teirstein P. Quantitative angiographic analysis of stent restenosis in the scripps coronary radiation to inhibit intimal proliferation post stenting (SCRIPPS) trial. The American Journal Of Cardiology 1999, 84: 410-414. PMID: 10468078, DOI: 10.1016/s0002-9149(99)00325-2.Peer-Reviewed Original ResearchConceptsStent marginsStenting TrialStent restenosisIr-192Quantitative angiographic resultsQuantitative angiographic analysisLower restenosis ratePercent diameter stenosisLower relative riskPlacebo sourcesAngiographic resultsRestenosis rateDiameter stenosisAngiographic analysisRelative riskRestenosisTreatment lengthIridium-192Successful interventionsTrialsFurther studiesPatientsTreatmentStenosisFollowComparative analysis of early and late angiographic outcomes using two quantitative algorithms in the Balloon versus Optimal Atherectomy Trial (BOAT)
Lansky A, Popma J, Cutlip D, Ho K, Abizaid A, Saucedo J, Zhang Y, Senerchia C, Kuntz R, Leon M, Baim D, Investigators F. Comparative analysis of early and late angiographic outcomes using two quantitative algorithms in the Balloon versus Optimal Atherectomy Trial (BOAT). The American Journal Of Cardiology 1999, 83: 1611-1616. PMID: 10392863, DOI: 10.1016/s0002-9149(99)00166-6.Peer-Reviewed Original ResearchConceptsMinimal lumen diameterPercent diameter stenosisBaseline minimal lumen diameterDiameter stenosisReference diameterDirectional atherectomyBaseline measurementsBaseline reference diameterQuantitative angiographic analysisLate angiographic outcomeAngiographic findingsAngiographic outcomesRestenosis rateBalloon angioplastyAngiographic analysisTreatment benefitTreatment groupsAngiographic laboratoryLumen diameterStenosisIndependent observersLesion irregularityAtherectomyPatientsTrialsLow- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose